Sissetulev kiriAvalik
Euroopa farmakopöa töökava asjus
Ravimiamet · 23. aprill 2026
- Viit
- REP-1/2346-1
- Registreeritud
- 23. aprill 2026
- Dokumendi liik
- Sissetulev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Saabumis/saatmisviis
- e-post
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2026
- Vastutaja
- Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)
Sisu (failidest)
Signe Leito
Saatja: [email protected]
Saatmisaeg: neljapäev, 23. aprill 2026 12:58
Adressaat: Signe Leito
Teema: Addition of Lisdexamfetamine dimesylate to the Ph. Eur. work programme:
EDQM-2026-02041-mail
Järeltegevuse lipp: Järeltegevus
Olekulipp: Lipuga märgitud
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke
ja faile mitte avada.
Please make sure to include in any reply our mail reference: EDQM-2026-02041-mail
****************************************************************************
European Pharmacopoeia Commission Secretariat
LETTER FOR THE ATTENTION OF NPAs
Copy: Presidium
Dear Colleagues,
Please find below the link to a survey being carried out concerning the proposed addition of
Lisdexamfetamine dimesylate to the Ph. Eur. work programme.
In order to have access to the survey, please copy and paste this link into your Internet browser:
https://survey.edqm.eu/index.php?r=survey/index&sid=553277&lang=en
Deadline for replies: 23 May 2026
With kind regards,
On behalf of Dr Jaume Sanz-Biset
Mireille Kopf
Secretarial Assistant
European Pharmacopoeia Department
EDQM - Council of Europe
Tel.: +33 (0)3 88 41 28 53 / Fax: +33 (0)3 88 41 27 71
https://www.edqm.eu / https://store.edqm.eu
Stay connected with the EDQM
****************************************************************************
1
Please make sure to include in any reply our mail reference: EDQM-2026-02041-mail
2